LL-37: Research on the Human Cathelicidin Antimicrobial Peptide and Its Immunomodulatory Biology

Introduction: Where Innate Immunity Meets Peptide Biology

LL-37 is the only known human cathelicidin peptide — an antimicrobial peptide produced by the innate immune system as a first line of defense against infection. Its name reflects its structure: two leucine (L) residues at the N-terminus followed by 35 additional amino acids, giving it a 37-amino acid total length. Discovered as the active cleavage product of the precursor protein hCAP18 (human cationic antimicrobial protein 18), LL-37 has been studied intensively since the 1990s and represents one of the most characterized host defense peptides in the scientific literature.

What has made LL-37 particularly interesting to researchers is that its biological functions extend far beyond simple antimicrobial killing. Published research has documented roles for LL-37 in immunomodulation, wound healing, angiogenesis, cancer biology, and inflammation resolution — a breadth that has positioned it as a model compound for understanding the intersection of innate immunity and tissue biology.

This article reviews the published research on LL-37, covering its natural biology, proposed mechanisms, preclinical findings, and emerging clinical research. All information is for educational purposes only.

Natural Biology: What LL-37 Is and Where It Comes From

LL-37 is produced primarily by neutrophils, macrophages, monocytes, and epithelial cells lining the skin, respiratory tract, and gastrointestinal mucosa. It is derived from the precursor protein hCAP18, which is cleaved by extracellular serine proteases to release the active LL-37 fragment. This processing is regulated by inflammatory stimuli, vitamin D signaling (which directly upregulates hCAP18/LL-37 expression in epithelial cells), and microbial signals.

Circulating and tissue concentrations of LL-37 are typically low under homeostatic conditions but rise significantly in response to infection, inflammation, and injury — a pattern consistent with its proposed role as an on-demand defense and repair peptide.

LL-37 is also found in specific secretions, including breast milk (where it is proposed to contribute to innate immunity in neonates), wound fluid, and saliva. Its expression in diverse tissues reflects its broad physiological role beyond the immune compartment.

Antimicrobial Mechanism: Membrane Disruption

The antimicrobial activity of LL-37 is primarily attributable to its amphipathic alpha-helical structure. When interacting with bacterial membranes, LL-37 adopts a helical conformation with hydrophobic residues on one face and cationic (positively charged) residues on the other. This structure allows it to insert into and disrupt negatively charged bacterial membranes through mechanisms that include toroidal pore formation, carpet-like membrane disintegration, and translocation into the cytoplasm.

Key features of LL-37’s antimicrobial mechanism include:

• Broad-spectrum activity: LL-37 has documented antimicrobial effects against gram-positive and gram-negative bacteria, fungi, and viruses in vitro, including pathogens relevant to wound infections, respiratory infections, and urinary tract infections
• Low resistance development: Because LL-37 targets bacterial membrane structure rather than a specific molecular target like a receptor or enzyme, bacteria have limited ability to develop resistance through point mutations — a feature that has attracted significant pharmaceutical research interest given the global challenge of antibiotic resistance
• Biofilm disruption: LL-37 has been studied for its ability to inhibit and disrupt bacterial biofilms — organized surface-attached communities of bacteria that are significantly more resistant to conventional antibiotics and are associated with chronic wound infections and device-associated infections

Immunomodulatory Functions

Beyond direct antimicrobial killing, LL-37’s immunomodulatory properties have become a major focus of research:

Cytokine Modulation

LL-37 has complex and sometimes paradoxical effects on cytokine signaling. On one hand, it can activate dendritic cells and promote adaptive immune responses. On the other, it has been shown to inhibit LPS-mediated (lipopolysaccharide) inflammatory signaling — a key innate immune trigger from gram-negative bacteria — by binding and neutralizing LPS before it can activate TLR4. This dual capacity to promote appropriate immune activation while dampening potentially harmful excessive inflammation (endotoxemia) reflects the sophisticated immunomodulatory role proposed for host defense peptides.

Chemotaxis and Immune Cell Recruitment

LL-37 acts as a chemotactic agent — it directly recruits immune cells to sites of infection and injury. It promotes the migration of neutrophils, monocytes, and mast cells to sites of inflammation through receptor-mediated signaling. This recruitment function positions LL-37 as a bridge between the immediate detection of infection and the organized cellular response.

Mast Cell Activation

LL-37 is one of the known activators of mast cells — immune cells located throughout tissues, particularly at mucosal surfaces and in connective tissue. Mast cell activation by LL-37 contributes to immune amplification and histamine release, a relationship that has also been studied in the context of conditions like rosacea and atopic dermatitis, where LL-37 dysregulation has been implicated.

Wound Healing and Tissue Repair

LL-37 has been studied extensively in wound healing contexts, where its role extends beyond antimicrobial protection to include direct tissue repair signaling:

Keratinocyte and Fibroblast Biology

Published in vitro data document that LL-37 promotes keratinocyte migration and proliferation — key cellular events in wound re-epithelialization — through EGFR (epidermal growth factor receptor) transactivation. It also promotes fibroblast migration, contributing to the stromal repair processes underlying wound closure.

Angiogenesis

LL-37 promotes angiogenesis through induction of VEGF (vascular endothelial growth factor) expression and direct effects on endothelial cell biology. The angiogenic component of LL-37’s wound healing activity is considered important for revascularization of healing tissue.

Chronic Wound Research

Interestingly, LL-37 levels have been found to be reduced in chronic wounds compared to acute wounds — suggesting that insufficient LL-37 production may contribute to impaired healing in conditions like diabetic foot ulcers and venous leg ulcers. This observation has driven interest in exogenous LL-37 supplementation or LL-37-based therapeutics for chronic wound applications.

Disease Biology: LL-37 in Skin Conditions

Rosacea

LL-37 has been identified as a significant contributor to rosacea pathophysiology. In rosacea-affected skin, abnormal processing of the hCAP18 precursor produces elevated LL-37 levels and aberrant LL-37 fragments that appear to drive the vascular and inflammatory features of the condition. This research has established LL-37 not only as a potential therapeutic molecule but also as a target whose dysregulation contributes to disease.

Psoriasis

In psoriasis, LL-37 has been identified as a key mediator of the autoimmune component of the disease. LL-37 can form complexes with self-DNA, creating immune-stimulatory aggregates that activate plasmacytoid dendritic cells through TLR9, driving interferon production and initiating the autoimmune cascade. This mechanistic insight has influenced our understanding of psoriasis as an autoinflammatory condition with an innate immunity component.

Atopic Dermatitis

In atopic dermatitis (eczema), LL-37 is paradoxically reduced in affected skin despite the inflammatory context, contributing to the increased susceptibility to skin infection that is a hallmark of this condition. Research into restoring LL-37 expression in atopic skin represents an active area of investigation.

Cancer Biology Research

LL-37’s effects on cancer biology are complex and context-dependent — a feature that reflects the broader complexity of the compound’s immunological profile:

• In some cancer cell line studies, LL-37 has demonstrated direct cytotoxic activity against cancer cells through membrane disruption
• In other contexts, particularly ovarian and breast cancer research, LL-37 expression has been associated with tumor promotion through its pro-angiogenic and EGFR-activating activities
• The cancer biology of LL-37 is an active research area with conflicting findings across different cancer types, highlighting the difficulty of drawing general conclusions about pro- or anti-tumor roles

Pharmaceutical Development Challenges

Despite the strong scientific rationale and broad biological activity, LL-37 presents significant pharmaceutical development challenges:

• Proteolytic instability: LL-37 is rapidly degraded by tissue proteases, limiting its bioavailability and duration of action
• Cytotoxicity at high doses: Like many amphipathic cationic peptides, LL-37 can be toxic to mammalian cells at elevated concentrations, creating a narrow therapeutic window in some applications
• Complex immunological effects: The dual activating-and-modulating nature of LL-37’s immune effects makes predicting its overall effect in complex disease states challenging

These challenges have directed research toward shorter, more stable LL-37-derived fragments and synthetic analogues designed to preserve specific activities while reducing toxicity and improving stability.

Research Status and Summary

LL-37 is an endogenous human peptide with an extensive published research literature spanning antimicrobial biology, wound healing, skin disease, immunology, and cancer biology. It is not a pharmaceutical drug — there are no FDA-approved LL-37-based therapeutic products — though its derivatives and analogues are in various stages of preclinical and early clinical investigation for applications including antibiotic-resistant infection, wound healing, and inflammatory skin conditions.

For researchers studying host defense peptides, innate immunity, skin biology, or wound healing, LL-37’s documented biology provides a rich scientific foundation and a model for how naturally occurring antimicrobial peptides function at the interface of immune defense and tissue repair.

All content on Peptide Research Blog is for educational and research purposes only. LL-37 is not an approved pharmaceutical product. This content does not constitute medical advice.